



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

29th October, 2026

Corporate Relationship Department
M/s. BSE Ltd.
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir / Madam

Sub: - Paper Publications

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find enclosed the copies of the newspaper Publications as appeared on 29th October, 2026 on **Financial Express**, **Jana Satta** and **Surya** regarding the Basis of Allotment of the Rights Issue of the Company.

The above publications are available on the website of the Company.

Thanking you

Yours faithfully
For NATCO Pharma Limited

VENKAT
RAMESH
CHEKURI

Digitally signed by
VENKAT RAMESH CHEKURI
DN: cn=VENKAT RAMESH CHEKURI,
o=NATCO PHARMA LIMITED, ou=, email=venkat.ramesh@natcopharma.co.in, c=IN

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Mahindra HOME FINANCE

मुद्रित नं. 203, अग्रिमो विविधित, विरामल अग्रस्य कोपोरिटे पाके, फायर ब्रिगेड स्टेशन के सामने, कामानी जंक्शन, एन.बी.एस. मेन रोड, कुर्ना (केर.) मुंबई- 400070

टेलीफोन: +91 22 6292 9800

शाखा/पंजीकृत कार्यालय: नवीय तल, प्लॉट नं. 46-47, श्रीवाय टॉवर, कांमो कॉलोनी, आसुपानी मार्ग, वैशाली नगर, जयपुर, राजस्थान - 302021

नीलामी विक्रय सूचना

विनीय आस्तिवो का प्रतिभूतिकरण एवं पुनर्गठन तथा प्रतिभूति हित प्रवर्तन अधिनियम, 2002 की धारा 13(4) के साथ पठित प्रतिभूति हित (प्रवर्तन) नियम, 2002 के नियम 8(5) एवं (6) तथा 9 के अंतर्गत नीलामी द्वारा प्रतिभूत आस्ति के विक्रय हेतु सार्वजनिक सूचना।

विनीय आस्तिवो का प्रतिभूतिकरण एवं पुनर्गठन तथा प्रतिभूति हित प्रवर्तन अधिनियम, 2002 (जिसे यहां इसके पष्ठान्त 'संकेपी अधिनियम' कहा गया है) की धारा 13(4) तथा प्रतिभूति हित (प्रवर्तन) नियम, 2002 (जिसे यहां इसके पष्ठान्त 'नियम' कहा गया है) के नियम 8 एवं 9 के अंतर्गत प्राप्त उक्तियों के प्रयोग में, प्रतिभूत प्रयोगों की यन्तुली के प्रवर्तन में, प्रतिभूत लेनदार मेसर्स महिन्द्रा रूयल हाउसिंग फाइनेंस लिमिटेड (जिसे यहां इसके पष्ठान्त 'एमआरएफएफएल' कहा गया है) के प्राधिकृत अधिकारी ने प्रतिभूत आस्ति (अवयव सम्पत्ति) को, जिसका कर्जा प्रतिभूत लेनदार के प्राधिकृत अधिकारी द्वारा संकेपी अधिनियम की धारा 13(4) के अंतर्गत लिया जा चुका है तथा जिसका कर्जाने लेने किया गया है, को 'जैसा है जहाँ है', 'जैसा है जो है' और 'जो कुछ भी है' के आधार पर चेकन का निर्णय लिया है, और संबंधित उक्तियों/चंयककर्ताओं, उनके प्रतिनिधियों, जो भी लागू हों, सहित आमजन एवं सभी संबंधित व्यक्तियों को एनूद्वारा सूचित किया जाता है कि नीचे सूचीबद्ध प्रतिभूत आस्तिवो का नीलामी के माध्यम में विक्रय किया जाएगा।

प्रीलाप्री की उक्तियाँ: "महिन्द्रा रूयल हाउसिंग फाइनेंस लिमिटेड, नवीय तल, प्लॉट नं. 46 - 47, श्रीवाय टॉवर, कांमो कॉलोनी, आसुपानी मार्ग, वैशाली नगर, जयपुर (राज.) - 302021" नीलामी की दिनांक एवं समय: 30.11.2026 को सोपहर 12.00 बजे से 1.30 बजे तक। योनी जुड़ित सति: रु. 5,000/-

क्र.सं.	अग्रणी एवं सह-अग्रणी का नाम / पता	चकाया सति / प्रतिभूत अग्रण	प्रतिभूत आस्ति/सम्पत्तियों का विवरण	आरक्षित मूल्य / धरोहर सति (डैमटडी)
1.	श्री इन्द्रमल सुकर पुत्र श्री मांगी लाल सुकर (आवेक) श्रीमती नेमी देवी सुकर पत्नी श्री इन्द्रमल सुकर (सह-आवेक) पडु नं. 09, कुकर मोहल्ला, सांवर, उदपुर, राजस्थान- 313206	रु. 4,93,976/- (चार लाख नितानवे हजार नौ सौ छित्तर रुपये मात्र) दिनांक: 05-05-2022 से व्याज, लागत एवं अन्य शुल्क आदि सहित।	सम्पत्ति के सभी भाग एवं अंग, जिसका पता पडु नं. 519, नगरपालिका कार्यालय फतेहनगर द्वारा जारी, सनवाई, जिला उदपुर, राजस्थान है तथा जिसका क्षेत्रफल 297.50 वर्गगज है। सीमाएं- पूर्व- रास्ता, पश्चिम- श्री भंकर लाल का मकान, उत्तर- श्री मांगी लाल का मकान, दक्षिण- श्री कालूय का मकान।	आरक्षित मूल्य- रु. 4,47,000/- (चार लाख सैतानीस हजार रुपये मात्र) धरोहर सति:- रु. 44,700/- (चौवालीस हजार सात नौ रुपये मात्र)
2.	श्री ईश्वर सिंह पुत्र खुबीर सिंह (आवेक) श्रीमती शर्मिला देवी पत्नी ईश्वर सिंह (सह-आवेक) पडु नं. 047, ग्राम पदमाड़ा खुर्द, ग्राम पंचायत मजरी खोला, पंचायत समिति मुंडावर, अलवर, राजस्थान- 301427	रु. 6,93,404.35/- (छह लाख नितानवे हजार चार सौ चार रुपये और पैंतीस पैसे मात्र) दिनांक: 05-02-2026 से व्याज, लागत एवं अन्य शुल्क आदि सहित।	सम्पत्ति के सभी भाग एवं अंग, जिसका पता पडु नं. 047, ग्राम पदमाड़ा खुर्द, ग्राम पंचायत मजरी खोला, पंचायत समिति मुंडावर, अलवर, राजस्थान है तथा जिसका क्षेत्रफल लगभग 1200 वर्गफुट है। सीमाएं- पूर्व- सक्कारी विद्यालय की भूमि, पश्चिम- सड़क, उत्तर- सरसीत एवं खुबीर का निवास, दक्षिण- गली।	आरक्षित मूल्य- रु. 5,61,000/- (पाँच लाख इकसठ हजार रुपये मात्र) धरोहर सति:- रु. 56,100/- (छपन हजार एक सौ रुपये मात्र)

निर्धारित निविदा प्रयोगों में मोहरावर प्रस्ताव/योनी, धरोहर सति सहित, जमा करने की अंतिम तिथि 28.11.2026 को सोपहर 3 बजे से पूर्व है, जो ऊपर उल्लेखित शाखा कार्यालय के पते पर जमा की जाएगी। जो निविदाएँ भरी नहीं गई हैं अथवा जो अंतिम तिथि के पष्ठान्त गमा होगी, उन्हें अवैध निविदा माना जाएगा। धारोहर सति पर कोई व्याज देय नहीं होगा।

सम्पत्ति के प्रस्ताव खोलने की तिथि 30.11.2026 है तथा निविदाएँ ऊपर उल्लेखित शाखा कार्यालय के पते पर प्राप्त: 10.00 बजे से सांय 04.00 बजे के मध्य है।

अवयव सम्पत्ति के निरीक्षण की तिथि 23.11.2026 को प्रातः 10.00 बजे से सांय 04.00 बजे के मध्य है।

नीलामी 'जैसा है जहाँ है', 'जैसा है जो है' तथा 'जो कुछ भी है' के आधार पर की जा रहे है तथा 'अंकिताइन' आयोजित की जाएगी। नीलामी 'महिन्द्रा रूयल हाउसिंग फाइनेंस लिमिटेड, नवीय तल, प्लॉट नं. 46 - 47, श्रीवाय टॉवर, कांमो कॉलोनी, आसुपानी मार्ग, वैशाली नगर, जयपुर (राज.) - 302021' में आयोजित की जाएगी। नीलामी योनी प्रत्य, घोषणा-पत्र तथा नीलामी विक्रय के समस्त नियम एवं शर्तों सहित नीलामी निविदा वस्तावर वेबसाइट www.mahindrahomefinance.com पर उपलब्ध है। प्राधिकृत अधिकारी श्री नरेन्द्र चौहान (मोबाइल) 9887399395 (NARENDRA.CHOUDHAN@mahindrahomefinance.com) तथा श्री गुरांक शर्मा (मोबाइल) 9824697979 (SHASHANK.SHARMA@mahindrahomefinance.com) से संपर्क करें।

दिनांक: 27.10.2026 स्थान: राजस्थान प्राधिकृत अधिकारी, महिन्द्रा रूयल हाउसिंग फाइनेंस लिमिटेड

This advertisement is for information purposes only and neither constitutes an offer or an invitation or a recommendation to purchase, to hold or sell securities nor for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of Offer dated September 28, 2026 (the "Letter of Offer" or "LOF") filed with National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE"), and also filed with the Securities and Exchange Board of India ("SEBI").

NATCO

NATCO PHARMA LIMITED

NATCO Pharma Limited (the "Company") was incorporated as a private limited company under the name "Natco Fine Pharmaceuticals Private Limited" under the Companies Act, 1956 and was granted a certificate of incorporation dated September 19, 1981 by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company became a deemed public company with effect from July 1, 1992, pursuant to our intimation to the Registrar of Companies, Andhra Pradesh at Hyderabad by letter dated May 29, 1992, and the word "Private" was deleted from the name of our Company. Subsequently, the name of our Company was changed to "NATCO Pharma Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad on February 18, 1993. Subsequently, our Company was converted into a public limited company and a fresh certificate of incorporation consequent upon conversion dated December 30, 1994, was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. For further details, see "General Information" on page 47 of the LOF.

Registered and Corporate Office: "NATCO House", Road No. 2, Banjara Hills, Hyderabad - 500034, Telangana, India.
Tel: +91 40 2354 7532; **Contact Person:** Chekuri Venkat Ramesh, Company Secretary and Compliance Officer
E-mail: investors@natcopharma.co.in; **Website:** www.natcopharma.co.in; **Corporate Identity Number:** L24230TG1981PLC003201

PROMOTERS OF OUR COMPANY:

VENKAIHA CHOWDARY NANNAPANENI, DURGA DEVI NANNAPANENI, RAJEEV NANNAPANENI, NEELIMA SITA NANNAPANENI, VENKAIHA CHOWDARY NANNAPANENI HUF, VISTRA ITCL INDIA LIMITED A/C NEELIMA NANNAPANENI TRUST, VISTRA ITCL INDIA LIMITED A/C DURGADEVI FAMILY TRUST, VISTRA ITCL INDIA LIMITED A/C VCN FAMILY TRUST AND SAU FAMILY TRUST

ISSUE OF UP TO 17,058,082 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹2 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹750 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹748 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹12,794 MILLION ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 2 RIGHTS EQUITY SHARES FOR EVERY 21 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT WAS ON OCTOBER 1, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 83 OF THE LOF.

BASIS OF ALLOTMENT

The Board of Directors of NATCO PHARMA LIMITED wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on Monday, October 12, 2026 and closed on Thursday, October 22, 2026 with the last date for on-market renunciation of Rights Entitlements on Friday, October 16, 2026. Out of the total 43,740 Applications for 22,544,304 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA"), 1,238 Applications for 53,201 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 42,502 Applications for 22,491,103 Rights Equity Shares, which was 131.85 % of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on October 23, 2026 by the Company, in consultation with the Registrar to the Issue and NSE, the Designated Stock Exchange for the Issue. The Fund-Raising Committee of the Company at their meeting held on October 23, 2026 pursuant to the delegation of authority by the Board of Directors, took on record the Basis of Allotment so approved, and approved the allotment of 17,058,082 Right Equity Shares to successful Applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and technical rejections have been considered for Allotment.

1) The break-up of valid Applications received through ASBA (after technical rejections) is given below:

Category	No. of Valid Applications Received	No. of Shares under valid Applications	No. of Rights Equity Shares accepted and Allotted against Rights Entitlement (A)	No. of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B)	Total Rights Equity Shares accepted and Allotted (A+B)
Eligible Equity Shareholders	42,188	11,853,960	7,007,848	3,455,721	10,463,569
Renouncees*	314	10,637,143	6,594,513	0	6,594,513
Total	42,502	22,491,103	13,602,361	3,455,721	17,058,082

2) Basis of Allotment:

Category	Total no. of applications received		Equity Shares applied for			Equity Shares Allotted		
	Number	%	Number	Value (₹)	%	Number	Value (₹)	%
Eligible Equity Shareholders	43,426	99.28%	11,907,161	8,930,370,750.00	52.82%	10,463,569	7,847,676,750.00	61.34%
Renouncees*	314	0.72%	10,637,143	7,977,857,250.00	47.18%	6,594,513	4,945,884,750.00	38.66%
Total	43,740	100.00%	22,544,304	16,908,228,000.00	100.00%	17,058,082	12,793,561,500.00	100.00%

*The investors (identified based on DPID & Client ID) whose names do not appear on the list of Eligible Equity Shareholders as on the Record Date and who hold the RES as on the Issue Closing Date and have applied in the Issue are considered Renouncees.

Intimations for Allotment / refund / rejection cases: The dispatch of Allotment Advice cum Unblocking Intimation to the investors, as applicable, commenced on October 26, 2026 and has been completed on October 26, 2026. The instructions to SCsBs for unblocking of funds in case of ASBA Applications were given on October 23, 2026. The listing application was filed with BSE and NSE on October 24, 2026, respectively and subsequently the listing approvals were received on October 26, 2026 from BSE and NSE respectively. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on October 26, 2026. For further details, see "Terms of Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" on page 108 of the Letter of Offer. Pursuant to the listing and trading approvals granted by BSE and NSE, the Rights Equity Shares Allotted in the Issue will commence trading on BSE and NSE on October 28, 2026 and shall be traded under the same ISIN INE987801026 as the existing Equity Shares. In accordance with the SEBI circular bearing reference no. SEBI/HOI/CFD/DIL2/CIRP/2020/13 dated January 22, 2020, the request for extinguishment of rights entitlement has been sent to NSDL & CDSL on October 26, 2026.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

Disclaimer clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of the NSE under the heading "Other Regulatory and Statutory Disclosures - Disclaimer Clause of NSE" on page 79 of the Letter of Offer.

Disclaimer clause of BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of the BSE Limited under the heading "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 80 of the Letter of Offer.

REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
KFINTECH KFin Technologies Limited Address: Selenium Tower-B, Plot No. 31 & 32 Gachibowli, Financial District, Nanakramguda, Serilingampally Hyderabad - 500 032, Telangana, India. Tel: +91 40 6716 2222/ 1800 309 4001 E-mail: natcopharma.rights@kfintech.com Investor Grievance ID: enward.ris@kfintech.com Contact Person: Williams R Website: www.kfintech.com SEBI Registration No.: INR0000000221	Chekuri Venkat Ramesh, Company Secretary and Compliance Officer "NATCO House" Road No. 2, Banjara Hills, Hyderabad - 500 034, Telangana, India Tel: +91 40 2354 7532; E-mail: venkatramesh.ch@natcopharma.co.in Investor may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-issue or post-issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCsB, giving complete details such as name, address, contact number(s), e-mail address of the sole/ first holder, folio number or demat account of the Applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCsB where the Application Form, or the plain paper application, as the case may be, was submitted by the ASBA Investors. For details on the ASBA process, see "Terms of Issue- Making of an Application through the ASBA Process" on page 87 of the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

For NATCO PHARMA LIMITED
On behalf of Board of Directors
Sd/-
Chekuri Venkat Ramesh
Company Secretary and Compliance Officer

NATCO PHARMA LIMITED has filed a Letter of Offer with Stock Exchanges on September 28, 2026 in connection with a rights issue of its Equity Shares. The letter of offer is available on the website of SEBI at www.sebi.gov.in, the website of the stock exchange at www.bseindia.com, the Company website at www.natcopharma.co.in and the website of registrar at www.kfintech.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with the SEBI and the stock exchanges, including the section titled "Risk Factors" on Page 14 of the Letter of Offer, for details of the same.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer or sale of securities in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States and will not be, registered under the US Securities Act of 1933, as amended, or an exemption from registration. The Rights Entitlements and the Rights Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable State Securities Laws. Accordingly, the Rights Equity Shares are only being offered and sold in "Offshore Transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act to eligible equity shareholders, located in jurisdictions where such offer and sale is permitted under the laws of such jurisdictions. The Offering to which this Letter of Offer relates is not, and under no circumstances is to be construed as, an Offering of any Rights Entitlements or Rights Equity Shares for sale in the United States or as a solicitation therein of an Offer to buy any of the said Securities. Accordingly, you should not forward or transmit the Letter of Offer into the United States at any time.

Adfactors 477/26

PRE-OFFER ADVERTISEMENT IN ACCORDANCE UNDER REGULATION 18(7) IN TERMS OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVER) REGULATIONS, 2011, AS AMENDED AND CORRIGENDUM TO THE DETAILED PUBLIC ANNOUNCEMENT WITH RESPECT TO THE OPEN OFFER TO THE PUBLIC SHAREHOLDERS OF

ISHAAN INFRASTRUCTURES AND SHELTERS LIMITED

Registered Office: 507-B, Titanium City Centre, NR Sachin Towers, 100 Feet Road, Anandnagar, Satellite, Jodhpur Char Rasta, Ahmedabad, Gujarat-380015

Email: ishaaninfra9@gmail.com; **Website:** www.ishaaninfra.in; **CIN:** L45300G1995PLC027912

This advertisement ("Offer Opening Public Announcement") is being issued by Novus Capital Advisors Private Limited (Formerly known as Fast Track Finsec Private Limited) ("Manager to the Offer") on behalf of Misun Pure Lights Private Limited ("Acquirer-1"), Ravi Prakash Bothra ("Acquirer-2"), Vaibhav Bothra ("Acquirer-3"), Rajesh Arora ("Acquirer-4") and Ashish Arora ("Acquirer-5") [collectively known as Acquirers] along with Yasha Bothra ("PAC 1"), Divyanshi Bothra ("PAC 2"), Sakshi Bothra ("PAC 3"), Rejesh Bothra ("PAC 4"), Sandeep Bothra ("PAC 5"), Priyanka Baid ("PAC 6"), Nirmala Bothra ("PAC 7") and Bothra Corp LLP ("PAC 8") [collectively known as PACs], pursuant to Regulation 18(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation, 2011, as amended ("SEBI (SAST) Regulation, 2011") ("Regulation"), in respect of the open offer to acquire upto 63,48,500* (Sixty-Three Lakh Forty-Eight Thousand Five Hundred) Equity Shares of INR 10/- (Rupees Ten Only) each of Ishaan Infrastructures and Shelters Limited ("Target Company" or "TC") representing 10.30% of the Expanded Voting Share Capital of the Target Company on a fully diluted basis carrying voting rights. The Detailed Public Statement ("DPS") with respect to the Offer was published in Financial Express (English-All Edition), Jansatta (Hindi-All Edition), Pratahkal (Mumbai Edition) and Financial Express (Gujarati Edition) on September 04, 2026.

"In terms of Regulation 7(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"), the open offer is required to be made for at least 26% (twenty six percent) of the Expanded Voting Share Capital of the Target Company. As on the date of 10th working day from closure of tendering period, the public shareholding of the Target Company comprises 10.30% (Ten Point Three Percent) of the Expanded Voting Share Capital, after excluding the Other Shareholders of the Transferor Company who are proposed allottees in the preferential issue and are considered as Deemed Persons Acting in Concert with the Acquirers for the purposes of this open offer and are, accordingly, ineligible to participate in the Open Offer in compliance with the provisions of regulation 7(6) of the SEBI (SAST) Regulations, 2011. Accordingly, the open offer is being made to the eligible public shareholders holding 10.30% (Ten-Point Three Percent) of the Expanded Voting Share Capital of the Target Company.

1. Offer Price:

The Offer price is INR 14/- (Rupees Fourteen Only) per fully paid-up equity share of face value INR 10/- (Rupees Ten Only) each ("Offer Price"). There has been no revision in the Offer Price.

2. Recommendations of the Committee of the Independent Directors of the Target Company

The Committee of the Independent Directors of the Target Company ("IDC") published its recommendations on the Offer on October 28, 2026 in the same newspapers where the DPS was published. Based on the review, IDC Members believe that the Offer is fair and reasonable in line with the SEBI (SAST) Regulations, 2011.

3. The Offer is not a competing offer in terms of the Regulation 20 of SEBI (SAST) Regulations, 2011. There was no competing offer to the Offer and the last date for making such competing offer has expired. The offer is not conditional upon any minimum level of acceptance in terms of Regulation 19(1) of SEBI SAST Regulations, 2011.

4. Dispatch of Letter of Offer to the public shareholders

The dispatch of the Letter of Offer to all the Public Shareholders of the Target Company holding Equity Share on the Identified Date i.e. Friday, October 16, 2026 has been completed through the E-mail and speed post on October 26, 2026. The Identified Date was relevant only for the purpose of determining the Public Shareholders as on such date to whom the Letter of Offer was to be sent. It is clarified that all the Holders (registered or unregistered) of Equity Shares (except the Acquirers, PACs, Other shareholders of Transferor Company & Promoters) are eligible to participate in the Offer any time during the Tendering Period. A copy of the Letter of Offer (which includes the Form of Acceptance-cum-Acknowledgment) is also available on the SEBI's website (www.sebi.gov.in).

5. Instructions to the Public Shareholders

a. **In case the shares are held in physical form**
Public Shareholders holding Equity Shares in physical form may participate in the Open Offer through their respective Selling Broker by providing the relevant information and documents as mentioned in paragraph 9.2 (page 38) of the LOF.

b. **In case the shares are held in demat form**
Public Shareholders who desire to tender their Equity Shares in the electronic / dematerialized form under the Offer would have to do so through their respective Selling Brokers by giving the details of Equity Shares they intend to tender under the Offer and as per the procedure specified in paragraph 9.3 under the heading of Procedure for tendering equity shares held in dematerialized form on page no. 39 of the LOF.

c. **Procedure for Tendering the Shares in case of Non-Receipt of the Letter of Offer**
In case of non-receipt of the LOF, the Public Shareholders holding the Equity Shares may download the same from the website of SEBI at www.sebi.gov.in, Manager to the Offer at www.novuscaps.com, and BSE at www.bseindia.com. Alternatively, they may participate in the Offer by providing their application in plain paper in writing signed by all shareholder(s), stating name, address, number of Equity Shares held, client ID number, DP name, DP ID number, number of Equity Shares tendered and other relevant documents and other relevant documents as mentioned in Paragraph 9.5 of page no.40 of the LOF.

6. Any other changes suggested by SEBI in their comments to be incorporated

In accordance with Regulation 16 of the SEBI (SAST) Regulations, the Draft Letter of Offer dated September 11, 2026 ("DLOF") was submitted to SEBI on same day i.e. September 11, 2026. SEBI issued its observations on the DLOF vide its communication letter dated October 14, 2026. The comments as specified in the Observation letter issued by SEBI have been duly incorporated in the Letter of Offer (LOF). These changes in the LOF include the following:

(i) on page no. 1,4,9,13,16, 18, 31, 33 and 35, modification in the percentage of open offer, (ii) on page no. 7, 16 and 31, the Total Expanded Voting Equity Share Capital revised, (iii) on Page no. 10,13,15, 16,17,26,29 and 31, number of shares to be issued pursuant to the Proposed Preferential Issue revised, (iv) on page no. 13,14,15,16 and 31, removal of name of Acquirer-4 from the list of allottees of the proposed preferential issue, (v) on Page no. 15, 16, 27 and 28, change in percentage of acquisition of BEPL and BCEPL by Target Company, (vi) on Page no. 16, addition of details in date wise developments in the instant matter, (vii) on Page no. 21, 22 and 23, modification in disclosures w.r.t. directorship of Acquirers and PAC-1 (viii) on Page no.26, modification in disclosure w.r.t. acquisition made by the Acquirers/PACs of shares of TC during the preceding 12 months from the date of PA, (ix) on page no. 29, change in composition of Board of Directors of Target Company, (x) on Page no. 31, modification in disclosure w.r.t. pre and post offer shareholding pattern of the Target Company, (xi) on Page no. 32, modification in disclosure w.r.t. volume-weighted average price paid or payable by the Acquirers for acquisition during the 52 weeks immediately preceding the date of the PA, (xii) on Page no. 36, modified disclosure w.r.t. Statutory and other approvals, (xiii) on Page no. 47 for copy of SEBI comments letter dated October 14, 2026 (xiv) on Page no. 02, disclosed that, shares held by persons other than the promoters during the open offer period which are under lock-in, are not permitted to be tendered in the open offer in accordance with regulation 16(7)(2) of SEBI (ICDR Regulations and if tendered, shall not be accepted in the open offer, as mentioned in SEBI Observation Letter in point 2.c (xv) on Page no. 3 for make a corrigendum to Detailed Public Statement (DPS) in all the newspapers, in which the original DPS was made, incorporating the comments stated at point 1.a & 1.b, before the date of opening of offer as mentioned in SEBI Observation Letter in point 2.d (xvi) on Page no. 37 for ensure compliance with SEBI Circular dated April 13, 2015 read with SEBI Circular dated December 09, 2016, with respect to acquisition of shares through stock exchange mechanism, and instructions specified by the stock exchanges in their respective circulars issued in connection with mechanism for acquisition of shares through Stock Exchanges as mentioned in SEBI Observation Letter in point 2.e.

7. Any other material changes from the Date of Public Announcement

There have been no material changes in relation to the Offer since the date of the PA, except the following: -

- The name of Mr. Rajesh Arora (Acquirer-4) has been removed from the list of Proposed Allottees and the proposed allotment of 12,72,840 Equity Shares of the Target Company to him pursuant to the proposed Preferential Issue ("underlying transaction") stands withdrawn due to his ineligibility for being included as a Proposed Allottee in terms of Regulation 159(1) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Consequently, the proposed Preferential Issue has been reduced, resulting in a corresponding reduction in the total Expanded Voting Share Capital of the Target Company.

8. Status of Statutory and Other Approvals

- As on the date of the LOF, there are no statutory approvals required to complete this Offer.
- However, in case any statutory approvals are required by the Acquirer at a later date before closure of the Tendering Period, the Offer shall be subject to such statutory approvals and the Acquirers shall make the necessary applications for such statutory approvals.
- NRI and OCB holders of the Equity Shares, if any, must obtain all requisite approvals required to tender the Equity Shares held by them in this Offer (including but not limited to, the approval from the RBI, since the Equity Shares validly tendered in this Offer will be acquired by a non-resident entity), if applicable, and submit such approvals along with the Form of Acceptance and other documents required to accept this Offer.

Further, if the Public Shareholders who are not persons resident in India (including NRIs, OCBs, FIs and FPIs) had required any approvals (including from the RBI or any other regulatory body) at the time of the original investment, in respect of the Equity Shares held by them currently, they will be required to submit copies of such previous approvals along with the other documents required to be tendered to accept this Offer.

If such approvals are not submitted, the Acquirers reserve the right to reject such Equity Shares tendered pursuant to this Offer. If the Equity Shares are held under the general permission of the RBI, the non-resident Shareholders should state that the Equity Shares are held under such general permission and whether such Equity Shares are held on a repatriable basis or a non-repatriable basis.

9. Schedule of Activities

The Schedule of Activities has been revised and the necessary changes have been incorporated in the LOF at all relevant places. The Revised Schedule of Activities is in compliance with the applicable provisions of SEBI (SAST) Regulations, 2011 and the same is as under:

Activity	Tentative Schedule	Revised Schedule
	Day and Date	Day and Date
Date of the Public Announcement	August 29, 2026 (Saturday)	August 29



Orbit Exports Limited
122, MISTRY BHAVAN, 2ND FLOOR, NEAR K C COLLEGE, DINSHAW WACHHA ROAD, CHURCHGATE, MUMBAI - 400 020. (MAH.) INDIA. TEL: +91-22-6625 6262, FAX: +91-22-22822031, E-mail: investors@orbitexports.com, Website: www.orbitexports.com; CIN NO: L40300MH1983PLC030872

STATEMENT OF UNAUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026



The Board of Directors of **Orbit Exports Limited**, at its meeting held on October 28, 2026, has approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 ("Financial Results").

The Financial Results, along with the Limited Review Report thereon, have been made available on the Company's website and can be accessed by scanning the QR code provided below.

For and behalf of Borad of Directors of Orbit Exports Limited
Sd/-
Pankaj Seth
Chairperson and Managing Director
(DIN:00027554)

Date: October 28, 2026
Place: Mumbai

Note: The above intimation is in accordance with the Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015



Detect and take down fake websites misusing your brand.

Get Seqrite **DRPS** [\[Scan the QR Code now!\]](#)

Quick Heal
QUICK HEAL TECHNOLOGIES LIMITED
Regd. Office: 1442 - 1445, Thube Park, Shivajinagar, Pune 411005
Phone: +91 20 66813232 CIN: L72200MH1995PLC091408 Email : cs@quickheal.co.in

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

Sr. No.	Particulars	Quarter ended		Half year ended		Year ended
		September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	
1	Total Income from Operation (including other income)	73.27	87.90	132.36	150.88	283.85
2	Profit/ (loss) before tax	4.33	10.28	(2.99)	3.28	(20.64)
3	Profit/ (loss) after tax	5.80	7.91	0.52	2.40	(10.93)
4	Total Comprehensive Income/ (loss) for the period	5.86	7.71	0.84	2.51	(9.79)
5	Equity Share Capital (Face value of ₹10/- each)	54.27	54.14	54.27	54.14	54.24
6	Other Equity (excluding revaluation reserves in Audited Balance Sheet as on March 31, 2026)	-	-	-	-	382.28
7	Earnings/ (loss) per share of ₹10 each: (not annualised)					
a)	Basic	1.03	1.43	0.09	0.43	(1.98)
b)	Diluted	1.03	1.42	0.09	0.43	(1.98)

Notes

1 The above is an extract of the unaudited consolidated financials results for the quarter and half year ended September 30, 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the aforesaid financials are available on the Stock Exchange websites [www.bseindia.com](#), [www.nseindia.com](#) and Company's website [www.quickheal.co.in](#).



For and on behalf of the Board of Directors
Sd/-
Kailash Katkar
Chairman & Managing Director
DIN No: 00397191

Place: Pune
Date : October 27, 2026

L&T Infra Investment Partners Advisory Private Limited
(For and on behalf of L&T Infra Investment Partners in the capacity of Investment Manager of L&T Infra Investment Partners)
Corporate Office: Brindavan, Plot No. 177, CST Road, Vidyasagar Marg New Mercedes Showroom, Kalina, Santacruz (East), Mumbai 400 098
Branch office: Mumbai



Public Notice for Invitation to Bid for AIF Fund Units

Inspirigence Advisors LLP ("Inspirigence"), under the capacity of Merchant Banker on behalf of L&T Infra Investment Partners Advisory Pvt Ltd ("LTIA") the investment manager of L&T Infra Investment Partners (LTIP), a SEBI registered Category-I Alternate Investment Fund is desirous of arranging bids for at least 25% of the total number of outstanding Fund units, given in the table below, from one or multiple bidders. LTIA hereby invites bids for acquisition of the Funds units comprising of unliquidated investments of LTIP on 100% cash basis. The sale of the said units is on basis of "As is where is", "As is what is", "Whatever there is" and "No Recourse".

Name of Issuer	Total no. of Outstanding Units	Principal Investment Amount (Rs. Cr.)*	Total claim Amount (Rs. Cr.)*
L&T Infra Investment Partners	3,15,08,573	139.83	1081

*The Principal Investment Amount represents the capital actually deployed by the Fund into the respective projects in the Renewable power and Telecom services sector.

*The Total Claim Amount reflects the derived committed value as established under the executed agreements with the underlying investee companies.

The interested parties shall, on or before November 13, 2026 by 6.00 p.m., submit their Expression of Interest ("EOI") to participate in the process, by sending an e-mail to [info@inspirigence.in](#) and [veritas.team@ltps.com](#) post which further details as to timelines for conducting due diligence, bid submission, etc. will be provided to the interested parties.

The broad terms of the offer are as follows:-

- The sale of the Fund units shall be on 100% Cash basis.
- Preliminary Information Memorandum ("PIM") will be shared with the Bidders who express their interest in acquiring the Fund units, subject to execution of a Non-disclosure Agreement, in the format prescribed by LTIA. The PIM will contain brief details of the unliquidated investments. Such information will be furnished on the basis of data available with LTIA and shall not be deemed to be a representation by LTIA about quality of assets. The Bidders shall conduct their own due diligence, investigation, analysis and independent verification.
- Due diligence / independent verification shall be undertaken by the participating Bidders at their own costs. By virtue of submission of the offer, it shall be deemed that the participating Bidders have conducted their own independent due diligence, investigation, analysis and independent verification in all aspects covering the liabilities, legal proceedings, encumbrances and any other dues etc., to their complete satisfaction.
- Detailed Process Note for the Bid Submission, timelines, Earnest Money Deposit amount shall be shared with the participants once the EOI is received from their end.
- Conditional and contingent offers shall be liable to be disqualified by LTIA.
- The participating Bidders shall not be entitled to withdraw or cancel their offer once submitted.
- Evaluation of the bids shall be at the sole discretion of LTIA.
- LTIA reserves the right to modify, alter the terms and conditions of sale and also reserves its right to reject any or all the bids, withdraw the units from sale, defer or cancel the sale, in totality at any stage, without assigning any reason whatsoever, if in the view of LTIA, the process is not viable or it would prejudicially affect the interest of the investors of the fund. All decisions of LTIA in regard to the sale process shall be final and conclusive. No claim for compensation on account of rejection of bids and /or rescinding / cancellation of sale process shall be entertained.
- The Successful Bid(s) will be shared with the investors of the Fund. The Bidder(s) will be notified about the Investors who agree to sell their units at the bid price.
- The bidder(s) will have to deposit the cash equivalent to the price of the said units in the escrow account maintained by LTIA for this specific purpose.
- In order to complete the sale process of the said units to the bidder, the Bid validity has to be till July 31, 2027.
- The Successful bidder(s) shall be solely and absolutely responsible for completion of all statutory, regulatory and other compliance and all costs and expenses towards stamp duty and registration charges towards transfer of units shall be borne by the successful bidder.
- In case of any further clarification, you may contact the following official:

Name of the official	Contact details
Mr. Ashish Jain (Inspirigence)	+91 7021945422
Mr. Ashwini Sharma (LTIA)	+91 98339 21210
Mr. Arya Shroff (LTIA)	+91 83693 62240

Date: October 29, 2026
Place: Mumbai

Authorized Signatory
L&T Infra Investment Partners Advisory Pvt Ltd.
(for and on behalf L&T Infra Investment Partners)



CARTRADE TECH LIMITED
Registered and Corporate Office: 1st Floor, Plot No. D-507, Shree Sawan Knowledge Park, TTC MIDC Industrial Area, Turbhe, Navi Mumbai - 400703
Tel: +91 22 6739 8888; Website: [https://www.cartradetech.com/](#); E-mail: [Investor@cartrade.com](#); Corporate Identity Number: L74900MH2000PLC126237

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED SEPTEMBER 30, 2026

The Board of Directors of CarTrade Tech Limited ("the Company"), at its meeting held on Wednesday, October 28, 2026, approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended September 30, 2026 ("Financial Results").

The Financial Results, together with the Limited Review Report, have been posted on the Company's website at [https://www.cartradetech.com/for-investors.html](#) and are also accessible via the Quick Response code ("QR code").

For and on behalf of the board of directors
CarTrade Tech Limited

Sd/-
Vinay Vinod Sanghi
Chairman and Managing Director
(DIN: 00309085)



Date: October 28, 2026
Place: Mumbai

This advertisement is for information purposes only and neither constitutes an offer or an invitation or a recommendation to purchase, to hold or sell securities nor for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of Offer dated September 28, 2026 (the "Letter of Offer" or "LOF") filed with National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE"), and also filed with the Securities and Exchange Board of India ("SEBI").



NATCO PHARMA LIMITED

NATCO Pharma Limited (the "Company") was incorporated as a private limited company under the name "Natco Fine Pharmaceuticals Private Limited" under the Companies Act, 1956 and was granted a certificate of incorporation dated September 19, 1981 by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company became a deemed public company with effect from July 1, 1992, pursuant to our intimation to the Registrar of Companies, Andhra Pradesh at Hyderabad by letter dated May 29, 1992, and the word "Private" was deleted from the name of our Company. Subsequently, the name of our Company was changed to "NATCO Pharma Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad on February 18, 1993. Subsequently, our Company was converted into a public limited company and a fresh certificate of incorporation consequent upon conversion dated December 30, 1994, was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. For further details, see "General Information" on page 47 of the LOF.

Registered and Corporate Office: "NATCO House", Road No. 2, Banjara Hills, Hyderabad - 500034, Telangana, India.
Tel: +91 40 2354 7532; **Contact Person:** Chekuri Venkat Ramesh, Company Secretary and Compliance Officer
E-mail: [investors@natcopharma.co.in](#); **Website:** [www.natcopharma.co.in](#); **Corporate Identity Number:** L24230TG1981PLC003201

PROMOTERS OF OUR COMPANY:
VENKAIAH CHOWDARY NANNAPANENI, DURGA DEVI NANNAPANENI, RAJEEV NANNAPANENI, NEELIMA NANNAPANENI, VENKAIAH CHOWDARY NANNAPANENI HUF, VISTRA ITCL INDIA LIMITED A/C NEELIMA NANNAPANENI TRUST, VISTRA ITCL INDIA LIMITED A/C DURGADEVI FAMILY TRUST, VISTRA ITCL INDIA LIMITED A/C VCN FAMILY TRUST AND SAU FAMILY TRUST

ISSUE OF UP TO 17,058,082 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹2 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹750 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹748 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹12,794 MILLION ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 2 RIGHTS EQUITY SHARES FOR EVERY 21 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT WAS ON OCTOBER 1, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 83 OF THE LOF.

BASIS OF ALLOTMENT

The Board of Directors of NATCO PHARMA LIMITED wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on Monday, October 12, 2026 and closed on Thursday, October 22, 2026 with the last date for on-market renunciation of Rights Entitlements on Friday, October 16, 2026. Out of the total 43,740 Applications for 22,544,304 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA"), 1,238 Applications for 53,201 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 42,502 Applications for 22,491,103 Rights Equity Shares, which was 131.85 % of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on October 23, 2026 by the Company, in consultation with the Registrar to the Issue and NSE, the Designated Stock Exchange for the Issue. The Fund-Raising Committee of the Company at their meeting held on October 23, 2026 pursuant to the delegation of authority by the Board of Directors, took on record the Basis of Allotment so approved, and approved the allotment of 17,058,082 Right Equity Shares to successful Applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and technical rejections have been considered for Allotment.

1) The break-up of valid Applications received through ASBA (after technical rejections) is given below:

Category	No. of Valid Applications Received	No. of Shares under valid Applications	No. of Rights Equity Shares accepted and Allotted against Rights Entitlement (A)	No. of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B)	Total Rights Equity Shares accepted and Allotted (A+B)
Eligible Equity Shareholders	42,188	11,853,960	7,007,848	3,455,721	10,463,569
Renounees*	314	10,637,143	6,594,513	0	6,594,513
Total	42,502	22,491,103	13,602,361	3,455,721	17,058,082

2) Basis of Allotment:

Category	Total no. of applications received		Equity Shares applied for			Equity Shares Allotted		
	Number	%	Number	Value (₹)	%	Number	Value (₹)	%
Eligible Equity Shareholders	43,426	99.28%	11,907,161	8,930,370,750.00	52.82%	10,463,569	7,847,676,750.00	61.34%
Renounees*	314	0.72%	10,637,143	7,977,857,250.00	47.18%	6,594,513	4,945,884,750.00	38.66%
Total	43,740	100.00%	22,544,304	16,908,228,000.00	100.00%	17,058,082	12,793,561,500.00	100.00%

*The investors (identified based on DPID & Client ID) whose names do not appear on the list of Eligible Equity Shareholders as on the Record Date and who hold the REs as on the Issue Closing Date and have applied in the Issue are considered Renounees.

Intimations for Allotment / refund / rejection cases: The dispatch of Allotment Advice cum Unblocking Intimation to the investors, as applicable, commenced on October 26, 2026 and has been completed on October 26, 2026. The instructions to SCBSs for unblocking of funds in case of ASBA Applications were given on October 23, 2026. The listing application was filed with BSE and NSE on October 24, 2026, respectively and subsequently the listing approvals were received on October 26, 2026 from BSE and NSE respectively. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on October 26, 2026. For further details, see "Terms of Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" on page 108 of the Letter of Offer. Pursuant to the listing and trading approvals granted by BSE and NSE, the Rights Equity Shares Allotted in the Issue will commence trading on BSE and NSE on October 28, 2026 and shall be traded under the same ISIN INE987B01026 as the existing Equity Shares. In accordance with the SEBI circular bearing reference No. SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of rights entitlement has been sent to NSDL & CDSL on October 26, 2026.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM.

Disclaimer clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of the NSE under the heading "Other Regulatory and Statutory Disclosures - Disclaimer Clause of NSE" on page 79 of the Letter of Offer.

Disclaimer clause of BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of the BSE Limited under the heading "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 80 of the Letter of Offer.

REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 KFin Technologies Limited Address: Selenium Tower-B, Plot No. 31 & 32 Gachibowli, Financial District, Nanakramguda, Serilingampally Hyderabad - 500 032, Telangana, India. Tel: +91 40 6716 2222/ 1800 309 4001 E-mail: natcopharma.rights@kfintech.com Investor Grievance ID: einward.ris@kfintech.com Contact Person: Williams R Website: www.kfintech.com SEBI Registration No.: INR000000221	Chekuri Venkat Ramesh, Company Secretary and Compliance Officer "NATCO House" Road No. 2, Banjara Hills, Hyderabad - 500 034, Telangana, India Tel: +91 40 2354 7532; E-mail: venkatramesh.ch@natcopharma.co.in Investor may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-issue or post-issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCBS, giving complete details such as name, address, contact number(s), e-mail address of the sole/ first holder, folio number or demat account of the Applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCBS where the Application Form, or the plain paper application, as the case may be, was submitted by the ASBA Investors. For details on the ASBA process, see "Terms of Issue- Making of an Application through the ASBA Process" on page 87 of the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

For NATCO PHARMA LIMITED
On behalf of Board of Directors
Sd/-
Chekuri Venkat Ramesh
Company Secretary and Compliance Officer

Place: Hyderabad, Telangana
Date: October 28, 2026

NATCO PHARMA LIMITED has filed a Letter of Offer with Stock Exchanges on September 28, 2026 in connection with a rights issue of its Equity Shares. The letter of offer is available on the website of SEBI at [www.sebi.gov.in](#), the website of the stock exchange at [www.bseindia.com](#), [www.nseindia.com](#), the Company website at [www.natcopharma.co.in](#) and the website of registrar at [www.kfintech.com](#). Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with the SEBI and the stock exchanges, including the section titled "Risk Factors" on Page 14 of the Letter of Offer, for details of the same.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer or sale of securities in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States and will not be, registered under the US Securities Act of 1933, as amended, or an exemption from registration. The Rights Entitlements and the Rights Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable State Securities Laws. Accordingly, the Rights Equity Shares are only being offered and sold in "Offshore Transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act to eligible equity shareholders, located in jurisdictions where such offer and sale is permitted under the laws of such jurisdictions. The Offering to which this Letter of Offer relates is not, and under no circumstances is to be construed as, an offering of any Rights Entitlements or Rights Equity Shares for sale in the United States or as a solicitation therein of an offer to buy any of the said Securities. Accordingly, you should not forward or transmit the Letter of Offer into the United States at any time.

Adfactores 477/26

ఏపీకి అండగా తెలంగాణ సర్కార్

- అర్బట్ తుపానీ వేళ విద్యుత్ పునరుద్ధరణకు సహకారం అవసరమైన సెబ్జంబిని, సామగ్రిని పంపేందుకు తెలంగాణ ప్రభుత్వం సంసిద్ధం
- ఏపీ విద్యుత్ శాఖ మంత్రి గొట్టిపాటి రవికి తెలంగాణ విద్యుత్ శాఖ మంత్రి భట్టి విక్రమార్క ఫోన్

హైదరాబాద్ : అర్బట్ తుపానీ వేళ ఏపీకి అండగా నిలిచేందుకు తెలంగాణ ప్రభుత్వం ముందుకొచ్చింది. ఏపీ విద్యుత్ శాఖ మంత్రి గొట్టిపాటి రవికి తెలంగాణ విద్యుత్ శాఖ మంత్రి భట్టి విక్రమార్క ఫోన్ చేసి తుపానీ తీవ్రత, జరిగిన నష్టంపై ఆరా తీశారు. ముఖ్యమంత్రి చంద్రబాబు అధ్యక్షతన చేపట్టిన నష్ట నివారణ చర్యలు, ఇప్పటివరకు జరిగిన నష్టం, విద్యుత్ పునరుద్ధరణ వనల గురించి గొట్టిపాటి వివరించారు. విద్యుత్ పునరుద్ధరణకు అవసరమైన సిబ్బందిని, సామగ్రిని పంపేందుకు తెలంగాణ ప్రభుత్వం సిద్ధంగా ఉందని భట్టి విక్రమార్క స్పష్టం చేశారు. కష్టకాలంలో ఏపీకి మద్దతుగా నిలిచేందుకు ముందుకొచ్చిన తెలంగాణ ప్రభుత్వానికి మంత్రి గొట్టిపాటి రవి దగ్గస్వాదాలు తెలిపారు.ఏపీలో అర్బట్ తుపాను బీభత్సం సృష్టిస్తోంది. ఎడతెరిపి లేకుండా కురుస్తోన్న వర్షాలకు వాగులు, వంకలు పొంగిపూర్ణమవుతున్నాయి. తుపాను కారణంగా రహదారులపై చెట్లు, విద్యుత్ స్తంభాలు విరిగిపడ్డాయి. దీంతో వందలాది గ్రామాలు అందకారంలో ఉన్నాయి.విద్యుత్ శాఖపై అధికారులతో సమీక్ష : అర్బట్ తుపాను ఎఫెక్ట్స్ మంత్రి గొట్టిపాటి విద్యుత్ శాఖపై

అధికారులతో సమీక్ష నిర్వహించారు. ‘ఉమ్మడి శ్రీకాకుళం, విజయనగరం, విశాఖ, ఉభయ గోదావరి, కృష్ణా జిల్లాల్లో విద్యుత్ వ్యవస్థ చెల్లడింది. పరిస్థితిని అర్థంచేసుకుని ప్రజలు సహకరించాలి. 883 ఫీడర్లకు 391 ఫీడర్లను చెల్లడినవిగా, కొన్నిచోట్ల ప్రమాదాల నివారణకు ముందస్తుగా విద్యుత్ సరఫరా నిలిపివేశాం. వర్షాలు పడేచోట విద్యుత్ పునరుద్ధరణ వనలకు ఆటంకం ఉంది. పరిస్థితి అనుకూలించగానే విద్యుత్ పునరుద్ధరణకు సిబ్బందిని సిద్ధంగా ఉన్నారు. ఎక్స్‌ప్రెస్‌లైన్ల తెగిపడినట్లు కనిపిస్తే 1912 కు ఫిర్మాలు చేయాలి. చెల్లుపడి చెల్లుతున్న విద్యుత్ స్తంభాలను పునరుద్ధరించే వనో్ సిబ్బంది ఉన్నారు’ మంత్రి గొట్టిపాటి తెలిపారు.నెలకొరిగిన విద్యుత్ స్తంభాలు : అర్బట్ తుపాను డాక్టర్ బి.ఆర్. అంబేద్కర్ కోసేనీమ్ జిల్లాను అతలాకుతలం చేసింది. జిల్లా వ్యాప్తంగా వీచిన ఉరుగుగాలులకు భారీ వృక్షాలు, విద్యుత్ స్తంభాలు నెలకొరిగి రాకపోకలకు తీవ్ర అంతరాయం ఏర్పడింది. వేలాది ఎకరాల్లో పరి, అరణి, కొబ్బరి పంటలు నేలమట్టమయ్యాయి. విద్యుత్, ఇంటర్నెట్ సేవలు నిలిచిపోవడంతో ప్రజలు తీవ్ర ఇబ్బందులు

ఎదుర్కొంటున్నారు.డాక్టర్ బి.ఆర్. అంబేద్కర్ కోసేనీమ్ జిల్లా కొత్తపేట నియోజకవర్గంలో తుపాను కారణంగా రహదారులపై చెట్లు, విద్యుత్ స్తంభాలు విరిగిపడ్డాయి. విపరీతమైన ఉరుగుగాలుల కారణంగా రావులపాలెం, ఆశ్రేయపురం, ఆలమూరు, కొత్తపేట మండలాల్లోని పలు ప్రాంతాల్లో కొబ్బరి చెట్లు నెలకొరిగాయి. ప్రభుత్వ భవనాల వద్ద ఉన్న చెట్లు భవనాలపై పడటంతో ప్రజలు తీవ్ర ఇబ్బందులు పడుతున్నారు.

ఉత్తరాంధ్ర జిల్లాల్లో గరిష్ట వర్షపాతాలు :
అర్బట్ తుపాను ప్రభావంతో ఉత్తరాంధ్ర జిల్లాల్లో గరిష్ట వర్షపాతాలు నమోదయ్యాయి. ఈ మేరకు అధికారులు వెల్లడించారు. విజయనగరం జిల్లా గరివిడిలో 26 సె.మీ, అనకాపల్లిలో 25 సె.మీ, శృంగవరపు కోట, వేపాడలో, చీపురుపల్లిలో 25 సె.మీ వర్షపాతం నమోదైనట్లు తెలిపారు. విశాఖపట్నం జిల్లా భీమునిపట్నం, మెంటాడ (విజయనగరం), ఎలమంచిలి (అనకాపల్లి)లో 24 సె.మీ, గంటూడ (విజయనగరం), రణస్థలం (శ్రీకాకుళం)లో 23 సె.మీ, గజపతిసగరం (విజయనగరం)లో, నెల్లిమర్ల (విజయనగరం), విశాఖ సిటీ, మెరకముడిదాం (విజయనగరం)లో 22 సె.మీ. విజయనగరంలో 21 సె.మీ వర్షపాతం నమోదైనట్లు అధికారులు వెల్లడించారు.



ఎల్‌ఎన్‌ఐ కరువుపై తక్షణ ఉపశమన చర్యలు చేపట్టాలి

- తెలంగాణలో కరువు నివారణకు సమగ్ర ప్రణాళిక అమలు చేయాలి
- పంట నష్టాలనివారణ, రుణమాఫీ, ఉచిత రేషన్ అందించాలి

తెలంగాణ బ్యారో ప్రతినిధి: ఎల్‌ఎన్‌ఐ ప్రభావంతో తెలంగాణలో తీవ్ర కరువు పరిస్థితులు నెలకొన్న నేపథ్యంలో ప్రభుత్వం తక్షణమే ప్రత్యేక సహాయ ప్యాకేజీ ప్రకటించాలని సీపీఐ(ఎం) రాష్ట్ర కమిటీ కోరింది. రాష్ట్రంలోని 31 జిల్లాల్లో 365 మండలాలను కరువు ప్రాంతాలుగా ప్రకటించిన నేపథ్యంలో గ్రామీణ స్థాయి నుంచి రాష్ట్రవ్యాప్తంగా సమగ్ర కరువు నివారణ ప్రణాళికను యుద్ధప్రాతిపదికన అమలు చేయాలని సూచించింది. డిప్యూటీ సీఎం మల్లా భట్టి విక్రమార్క నిర్వహించిన రాజకీయ పార్టీల సమావేశంలో సీపీఐ(ఎం) రాష్ట్ర కార్యదర్శి జాన్‌సెన్, మాజీ ఎమ్మెల్యే నంద్యాల నర్సింహారెడ్డి తమ ప్రతిపాదనలను సమర్పించారు. కరువు పరిస్థితులపై పూర్వస్థాయి సర్వే నిర్వహించి మిగిలిన ప్రభావిత మండలాలను కూడా కరువు



ప్రాంతాలుగా ప్రకటించాలని కోరారు. పంట నష్టపోయిన రైతులకు ఎకరాకు రూ.50 వేల ఛౌస్తున వాణిజ్య పంటలకు, ఇతర పంటలకు రూ.30 వేల పరిహారం అందించాలని డిమాండ్ చేశారు. రూ.2 లక్షలలోపు పంట రుణాలను మాఫీ చేయడంతోపాటు రైతు భరోసా, పీఎం కిసాన్ సాయం పెంచాలని సూచించారు. తెల్ల రేషన్‌కార్యదారులకు ఉచిత నిత్యావసర సరకులు, తాగునీరు, పశుగ్రామం అందించాలని కోరారు. ఉపాధి హామీ పనిదినాలను 200 రోజులకు పెంచి, రోజువారీ కూలీని రూ.800కు పెంచాలని ప్రతిపాదించారు. తక్కువ నీటితో పండే పంటలకు ఉచిత విత్తనాలు, ఎరువులు అందించాలని, రూ.800కు పెంచాలని ప్రతిపాదించారు. తక్కువ నీటితో పండే

వ్యవసాయానికి నిరంతర విద్యుత్ సరఫరా చేయాలని కోరారు. కరువు బాధితులను ఆదుకునేందుకు అవసర ప్రభుత్వ ఖర్చులు తగ్గించి, ఆ నిధులను సహాయ చర్యలకు మళ్లించాలని సీపీఐ(ఎం) జిల్లాపై చేసింది.

అమెరికాలో పెట్టుబడిదారులను ఆకర్షిస్తున్న తెలంగాణ పర్యాటకం

- “భారతదేశంలో ఇంకా వెలుగులోకి రాని అద్భుత రత్నం.”
- గ్లోబల్ టూరిజం కన్ఫ్లెక్స్ వ్యాఖ్య
- విదేశీ పట్టుబడుల కోసం అన్ని వసతులు ఏర్పాటు చేస్తుంది
- పర్యాటక శాఖ మంత్రి జాపల్లి కృష్ణారావు

తెలంగాణ బ్యారో, ప్రతినిధి: డిసెంబరులో హైదరాబాద్‌లో నిర్వహించనున్న ఇన్వెస్ట్ తెలంగాణ గ్లోబల్ సమ్మిట్ 2026కు ముందు, రాష్ట్రంలో విస్తారంగా ఉన్న ఇంకా పూర్తిగా వినియోగంలోకి రాని పర్యాటక పెట్టుబడి అవకాశాలను ప్రదర్శించేందుకు తెలంగాణ పర్యాటక శాఖ అమెరికాలోని పెట్టుబడిదారులు, పరిశ్రమ ప్రముఖులు మరియు ప్రభావశీల భారతీయ ప్రవాసులతో చురుకైన చర్చలు జరుపుతోంది. పర్యాటక శాఖ ప్రత్యేక ప్రధాన కార్యదర్శి వాణి ప్రసాద్, ఐఏఎస్, అమెరికాలోని ప్రముఖ వ్యాపారవేత్తలు, మీడియా ప్రముఖులు అధిక నికర విలువ కలిగిన పెట్టుబడిదారులతో చర్చలు జరిపి, తెలంగాణలో అందుబాటులో ఉన్న పెట్టుబడి అవకాశాలను, ముఖ్యంగా గుర్తింపబడిన ఎనిమిది ప్రత్యేక పర్యాటక ప్రాంతాల్లో ఉన్న అవకాశాలను వివరించారు. ఈ సమావేశాల్లో న్యూయార్క్ మేయర్

కార్యాలయ డిప్యూటీ చీఫ్ బిజినెస్ డెవలప్మెంట్ అఫీసర్ దిలీప్ చౌహాన్; ఇండో-అమెరికన్ అడ్వ్ కౌన్సిల్ ప్రచురణకర్త, సీఓఓ అధినేత సునీల్ హోలి, ప్రముఖ సాంకేతిక పారిశ్రామికవేత్తలు పెట్టుబడిదారులు అత్తూరి రిశిష్ పారిఖ్ పాల్గొన్నారు. రాష్ట్ర సామర్థ్యాన్ని వివరించిన వాణి ప్రసాద్, తెలంగాణలో అతీవ్రధ రంగం, పర్యాటక ఆకర్షణలు, మ్యూజియంలు, సాంకేతికత ఆధారిత సందర్శక సేవల మరియు డేటా ఆధారిత పరిష్కారాల్లో గణనీయమైన పాత్ర పోషిస్తున్న పెట్టుబడిదారుల అవకాశాలు ఉన్నాయని తెలిపారు. హైదరాబాద్‌కు అవతల ఉన్న పర్యాటక ప్రాంతాల్లో ప్రపంచ స్థాయి పర్యాటక మౌలిక సదుపాయాలను అభివృద్ధి చేయడంలో, సందర్శకుల అనుభవాలను మెరుగుపరచడంలో పెట్టుబడిదారుల కీలక పాత్ర పోషించగలరని అమె సేర్పొన్నారు. నేషనల్ జియోగ్రాఫిక్ మాజీ వైస్ ప్రెసిడెంట్ ప్రచురణకర్త డాన్



ప్రజా, తెలంగాణలో అభివృద్ధి చెందుతున్న పర్యాటక అవకాశాలను ప్రశంసించి, రాష్ట్రాన్ని భారతదేశంలో “ఇంకా వెలుగులోకి రాని అద్భుత రత్నం”గా అభివర్ణించారు. అమెరికాలోని ప్రయాణికులు పెట్టుబడిదారులకు సందేశం“తెలంగాణను కనుగొనండి”గా ఉండాలని సునీల్ హోలి అన్నారు. రెండు సగరాల మధ్య పెరుగుతున్న అనుబంధాన్ని ప్రస్తావిస్తూ, “న్యూయార్క్ హైదరాబాద్‌ను కలుస్తోంది” అనే సందేశాన్ని దిలీప్ చౌహాన్ వెల్లడించారు.

మోడికి ఖర్చే క్షమాపణలు చెప్పాలి



జీసీ నేత, బీజేపీ ఎంపీ. ఆర్. కృష్ణయ్య డిమాండ్
ఖర్చే చేసిన వ్యక్తిగత వ్యాఖ్యలను జాతీయ బీసీ సంక్షేమ సంఘం అధ్యక్షుడు, ఎంపీ ఆర్. కృష్ణయ్య విమర్శించారు. రాజకీయాల్లో విమర్శలు విధానాలు, పాలన, అభివృద్ధి అంశాలతో పరిమితం కావాలని, వ్యక్తిగత విమర్శలకు దిగడం తగదని హితవు పలికారు. మోడిపై చేసిన వ్యాఖ్యలను తక్షణమే వెనక్కి తీసుకుని బీజేపీకి క్షమాపణలు చెప్పాలని డిమాండ్ చేశారు. ప్రజా సమస్యలు, అభివృద్ధి, సంక్షేమంపై చర్చించాల్సిన కాంగ్రెస్ పార్టీ వ్యక్తిగత విమర్శలకు దిగడం సరికాదని విమర్శించారు. ప్రధానమంత్రి నరేంద్ర మోడీని రాజకీయంగా ఎదుర్కో తలనే ఇలాంటి వ్యాఖ్యలు చేస్తున్నారని ఆరోపించారు.

ఓబీసీ కాలమ్‌పై కాంగ్రెస్ పోరాడాలి

- నవంబర్ 1న ఢిల్లీ సభలో జీసీ కులగణన డిమాండ్‌ను చేర్చాలి
- డిసెంబర్ 14న రాంలీలా మైదానంలో జీసీల సింహగర్జన

తెలంగాణ బ్యారో ప్రతినిధి: ఓట చోటికి వ్యతిరేకంగా కాంగ్రెస్ పార్టీ చేస్తున్న పోరాటాన్ని స్వాగతిస్తున్నామని, అదే సమయంలో జాతీయ జనగణనలో ఓబీసీ కాలమ్ చేర్పాడనే డిమాండ్‌ను కూడా తన పోరాట విజెండాలో చేర్చాలని బీసీ సంక్షేమ సంఘం అధ్యక్షుడు జాజుల గౌడ్ కోరారు. హైదరాబాద్‌లో బీసీ విద్యార్థి సంఘం రాష్ట్ర అధ్యక్షుడు గొడుగు మహేష్ యాదవ్ అధ్యక్షతన జరిగిన బీసీ సంఘాల కోర్ కమిటీ సమావేశంలో ఆయన మాట్లాడారు. నవంబర్ 1న ఢిల్లీలోని రాంలీలా మైదానంలో కాంగ్రెస్ నిర్వహించే సభలో బీసీ కులగణన అంశాన్ని ప్రస్తావించి కేంద్రపై ఓబ్ది తీసుకురావాలని కాంగ్రెస్ అగ్రనేతలు మద్దతుని ఖర్చే, రాహుల్ గాంధీలకు విజ్ఞప్తి చేశారు. ఈ డిమాండ్‌పై కాంగ్రెస్ పోరాడే బీసీల సంస్థాగ్ర మద్దతు లభిస్తుందని తెలిపారు. బీసీ కులగణన చేపడతామని హామీ ఇచ్చి బీజేపీ మోసం చేసిందని ఆయన విమర్శించారు. దేశవ్యాప్తంగా 29 రాష్ట్రాల్లో నిరసనలు చేపట్టామని, తదుపరి



కార్యాచరణలో భాగంగా డిసెంబర్ 14న లక్నోలో మంచి బీసీలతో ఢిల్లీలోని రాంలీలా మైదానంలో బీసీల సింహగర్జన నిర్వహిస్తామని, డిసెంబర్ 15న పార్లమెంటు ముట్టడి చేపడతామని వెల్లడించారు. ఓబీసీ కాలమ్ కోసం పోరాడని రాజకీయ పార్టీలను బీసీలు నిలదీస్తారని హెచ్చరించారు. జనగణనలో ఓబీసీ కాలమ్ చేర్చకపోతే దేశంలో బీజేపీకి ఇదే చివరి పాలన అవుతుందని జాజుల శ్రీనివాస్ గౌడ్ అన్నారు. సమావేశంలో పలువురు బీసీ సంఘాల వాయకులు పాల్గొన్నారు.


లంచం అడిగితే 1064కు ఫిర్యాదు చేయండి



తెలంగాణ బ్యారో ప్రతినిధి: లంచం అడిగితే అవినీతి నిరోధక శాఖ (ఏసీబీ) దోలోఫ్రీ సంబర్ 1064కు ఫిర్యాదు చేయాలని అధికారులు సూచించారు. లంచం ఇవ్వడం, తీసుకోవడం రెండూ చట్టరీత్యా నేరాలు, ఫిర్యాదుదారుల వివరాలను గోప్యంగా ఉంచుతామని స్పష్టం చేశారు. విజిలెన్స్ అవగాహన వారోత్సవం--2026లో భాగంగా తెలంగాణ రవాణా శాఖ, ఏసీబీ సంయుక్త ఆధ్వర్యంలో బుద్ధవారం హైదరాబాద్‌లోని రవాణా కమిషనరీ కార్యాలయంలో అవగాహన కార్యక్రమం నిర్వహించారు. ‘సత్వినష్టతో సమ్మిడ్డి’ ఇతివృత్తంతో నిర్వహించిన ఈ కార్యక్రమంలో ఏసీబీ డీఎస్పీలు శ్రీనివాస్ రెడ్డి,

- రవాణా శాఖ, ఏసీబీ సంయుక్తంగా అవగాహన కార్యక్రమం
- ఆన్‌లైన్ సేవలతో పారదర్శకత.. దరఖాస్తులపై ప్రత్యేక నిఘా

లక్ష్మీకాంత్ రెడ్డి, చలపతి, రాజేష్ మాట్లాడారు. అవినీతిని అరికట్టడంలో అధికారులు, ప్రజలు బాధ్యతాయోగ్యం వ్యవహరించాలని కోరారు. రవాణా శాఖ జాయింట్ ట్రాన్స్‌పోర్ట్ కమిషన్‌పై ఎం. చంద్రశేఖర్ గౌడ్, శీవరంగయ్య, వెంకట రమణ మాట్లాడుతూ వాహనదారులకు పారదర్శక సేవలు అందించేందుకు పలు సంస్కరణలు చేపట్టినట్లు తెలిపారు. వాహన్, సారథి ఆన్‌లైన్ వ్యవస్థల ద్వారా రిజిస్ట్రేషన్, డ్రైవింగ్ లైసెన్స్, యాజమాన్య బదిలీ వంటి సేవలు అందిస్తున్నామని చెప్పారు. ఆన్‌లైన్ చెల్లింపులు, స్టాల్ బుకింగ్, ప్రత్యేక సంబంధకు ఈ-వేలం ద్వారా మద్దతుల ప్రమోషన్స్ తగ్గిస్తున్నట్లు వివరించారు. దరఖాస్తుల్లో అవసర జాప్యంపై చర్యలు తీసుకుంటామని, దశారులను అరికట్టేందుకు ఆకస్మిక తనిఖీలు నిర్వహిస్తున్నామని అధికారులు వెల్లడించారు. అవతరం అధికారులు, సిబ్బంది నిజాయితీ విధులు నిర్వహిస్తామని, అవినీతికి దూరంగా ఉంటామని సమగ్రత ప్రతిజ్ఞ చేశారు.



This advertisement is for information purposes only and neither constitutes an offer or an invitation or a recommendation to purchase, to hold or sell securities nor for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of Offer dated September 28, 2026 (the “**Letter of Offer**” or “**LOF**”) filed with National Stock Exchange of India Limited (“**NSE**”) and BSE Limited (“**BSE**”), and also filed with the Securities and Exchange Board of India (“**SEBI**”).

Please scan this QR Code to view the Letter of Offer

NATCO PHARMA LIMITED

NATCO Pharma Limited (the “**Company**”) was incorporated as a private limited company under the name “Natco Fine Pharmaceuticals Private Limited” under the Companies Act, 1956 and was granted a certificate of incorporation dated September 19, 1981 by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company became a deemed public company with effect from July 1, 1992, pursuant to our intimation to the Registrar of Companies, Andhra Pradesh at Hyderabad by letter dated May 29, 1992, and the word “Private” was deleted from the name of our Company. Subsequently, the name of our Company was changed to “NATCO Pharma Limited” and a fresh certificate of incorporation consequent upon change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad on February 18, 1993. Subsequently, our Company was converted into a public limited company and a fresh certificate of incorporation consequent upon conversion dated December 30, 1994, was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. For further details, see “**General Information**” on page 47 of the LOF.

Registered and Corporate Office: “NATCO House”, Road No. 2, Banjara Hills, Hyderabad - 500034, Telangana, India.
Tel: +91 40 2354 7532; **Contact Person:** Chekuri Venkat Ramesh, Company Secretary and Compliance Officer
E-mail: investors@natcopharma.co.in; **Website:** www.natcopharma.co.in; **Corporate Identity Number:** L24230TG1981PLC003201

PROMOTERS OF OUR COMPANY:
VENKAIHA CHOWDARY NANNAPANENI, DURGA DEVI NANNAPANENI, RAJEEV NANNAPANENI, NEELIMA SITA NANNAPANENI, VENKAIHA CHOWDARY NANNAPANENI HUF, VISTRA ITCL INDIA LIMITED A/C NEELIMA NANNAPANENI TRUST, VISTRA ITCL INDIA LIMITED A/C DURGADEVI FAMILY TRUST, VISTRA ITCL INDIA LIMITED A/C VCN FAMILY TRUST AND SAU FAMILY TRUST

ISSUE OF UP TO 17,058,082 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹2 EACH OF OUR COMPANY (THE “RIGHTS EQUITY SHARES”) FOR CASH AT A PRICE OF ₹750 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹748 PER RIGHTS EQUITY SHARE) (“ISSUE PRICE”) AGGREGATING UP TO ₹12.794 MILLION ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 2 RIGHTS EQUITY SHARES FOR EVERY 21 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT WAS ON OCTOBER 1, 2026 (“RECORD DATE”) (THE “ISSUE”). FOR FURTHER DETAILS, SEE “TERMS OF THE ISSUE” BEGINNING ON PAGE 83 OF THE LOF.

BASIS OF ALLOTMENT

The Board of Directors of NATCO PHARMA LIMITED wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on Monday, October 12, 2026 and closed on Thursday, October 22, 2026 with the last date for on-market renunciation of Rights Entitlements on Friday, October 16, 2026. Out of the total 43,740 Applications for 22,544,304 Rights Equity Shares, through the Application Supported by Blocked Amount (“ASBA”), 1,238 Applications for 53,201 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 42,502 Applications for 22,491,103 Rights Equity Shares, which was 131.85 % of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on October 23, 2026 by the Company, in consultation with the Registrar to the Issue and NSE, the Designated Stock Exchange for the Issue. The Fund-Raising Committee of the Company at their meeting held on October 23, 2026 pursuant to the delegation of authority by the Board of Directors, took on record the Basis of Allotment so approved, and approved the allotment of 17,058,082 Right Equity Shares to successful Applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and technical rejections have been considered for Allotment.

1) The break-up of valid Applications received through ASBA (after technical rejections) is given below:

Category	No. of Valid Applications Received	No. of Shares under valid Applications	No. of Rights Equity Shares accepted and Allotted against Rights Entitlement (A)	No. of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B)	Total Rights Equity Shares accepted and Allotted (A+B)
Eligible Equity Shareholders	42,188	11,853,960	7,007,848	3,455,721	10,463,569
Renouncees*	314	10,637,143	6,594,513	0	6,594,513
Total	42,502	22,491,103	13,602,361	3,455,721	17,058,082

2) Basis of Allotment:

Category	Total no. of applications received		Equity Shares applied for			Equity Shares Allotted		
	Number	%	Number	Value (₹)	%	Number	Value (₹)	%
Eligible Equity Shareholders	43,426	99.28%	11,907,161	8,930,370,750.00	52.82%	10,463,569	7,847,676,750.00	61.34%
Renouncees*	314	0.72%	10,637,143	7,977,857,250.00	47.18%	6,594,513	4,945,884,750.00	38.66%
Total	43,740	100.00%	22,544,304	16,908,228,000.00	100.00%	17,058,082	12,793,561,500.00	100.00%

**The investors (identified based on DPID & Client ID) whose names do not appear on the list of Eligible Equity Shareholders as on the Record Date and who hold the RES as on the Issue Closing Date and have applied in the Issue are considered Renouncees.*

Intimations for Allotment / refund / rejection cases: The dispatch of Allotment Advice cum Unblocking Intimation to the investors, as applicable, commenced on October 26, 2026 and has been completed on October 26, 2026. The instructions to CSBs for unblocking of funds in case of ASBA Applications were given on October 23, 2026. The listing application was filed with BSE and NSE on October 24, 2026, respectively and subsequently the listing approvals were received on October 26, 2026 from BSE and NSE respectively. The credit of Rights Equity Shares in dematerialised form to respective demat accounts of Allottees was completed on October 26, 2026. For further details, see “**Terms of Issue - Allotment Advice or Refund/Unblocking of ASBA Accounts**” on page 108 of the Letter of Offer. Pursuant to the listing and trading approvals granted by BSE and NSE, the Rights Equity Shares Allotted in the Issue will commence trading on BSE and NSE on October 28, 2026 and shall be traded under the same ISIN INE987B01026 as the existing Equity Shares. In accordance with the SEBI circular bearing reference No. SEBI/HO/CFD/DIL2/CIRP/2020/13 dated January 22, 2020, the request for extinguishment of rights entitlement has been sent to NSDL & CDSL on October 26, 2026.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

Disclaimer clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of the NSE under the heading “**Other Regulatory and Statutory Disclosures - Disclaimer Clause of NSE**” on page 79 of the Letter of Offer.

Disclaimer clause of BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of the BSE Limited under the heading “**Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE**” on page 80 of the Letter of Offer.

REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
KFin Technologies Limited Address: Selenium Tower-B, Plot No. 31 & 32 Gachibowli, Financial District, Nanakramguda, Serilingampally Hyderabad - 500 032, Telangana, India. Tel: +91 40 6716 2222/ 1800 309 4001 E-mail: natcopharma.rights@kfintech.com Investor Grievance ID: einward.ris@kfintech.com Contact Person: Williams R Website: www.kfintech.com SEBI Registration No.: INR000000221	Chekuri Venkat Ramesh, Company Secretary and Compliance Officer “NATCO House” Road No. 2, Banjara Hills, Hyderabad – 500 034, Telangana, India Tel: +91 40 2354 7532; E-mail: venkataramesh.ch@natcopharma.co.in Investor may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-issue or post-issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the CSGB, giving complete details such as name, address, contact number(s), e-mail address of the sole/ first holder, folio number or demat account of the Applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the CSGB where the Application Form, or the plain paper application, as the case may be, was submitted by the ASBA Investors. For details on the ASBA process, see “Terms of Issue- Making of an Application through the ASBA Process” on page 87 of the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

Place: Hyderabad, Telangana
Date: October 28, 2026

For NATCO PHARMA LIMITED
On behalf of Board of Directors
Sd/-
Chekuri Venkat Ramesh
Company Secretary and Compliance Officer

NATCO PHARMA LIMITED has filed a Letter of Offer with Stock Exchanges on September 28, 2026 in connection with a rights issue of its Equity Shares. The letter of offer is available on the website of SEBI at www.sebi.gov.in, the website of the stock exchange at www.bseindia.com, www.nseindia.com, the Company website at www.natcopharma.co.in and the website of registrar at www.kfintech.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with the SEBI and the stock exchanges, including the section titled “**Risk Factors**” on Page 14 of the Letter of Offer, for details of the same.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer or sale of securities in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States and will not be, registered under the US Securities Act of 1933, as amended, or an exemption from registration. The Rights Entitlements and the Rights Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities act and applicable State Securities Laws. Accordingly, the Rights Equity Shares are only being offered and sold in “Offshore Transactions” as defined in, and in reliance on, Regulation S under the U.S. Securities Act to eligible equity shareholders, located in jurisdictions where such offer and sale is permitted under the laws of such jurisdictions. The Offering to which this Letter of Offer relates is not, and under no circumstances is to be construed as, an Offering of any Rights Entitlements or Rights Equity Shares for sale in the United States or as a solicitation therein of an Offer to buy any of the said Securities. Accordingly, you should not forward or transmit the Letter of Offer into the United States at any time.

Adactors 477/26